Research Paper Volume 11, Issue 24 pp 11905—11921

KIF20A promotes cellular malignant behavior and enhances resistance to chemotherapy in colorectal cancer through regulation of the JAK/STAT3 signaling pathway

class="figure-viewer-img"

Figure 7. KIF20A mediates malignant behaviors in CRC via the JAK/STAT3 signaling pathway. (A) Phosphorylation of JAK and STAT3 in different transfected groups was determined by western blot analysis. (B) Western blot analysis of phosphorylation of JAK and STAT3 in different transfected groups with or without the administration of JAK inhibitor, INCB. (C) Western blot analysis of phosphorylation of JAK and STAT3 in different transfected groups with or without the silence of STAT3. (D, E) Relative growth rate of different transfected groups with or without the administration of INCB or silence of STAT3. The comparison was made at indicated times. (FI) Colon formation assay of different transfected groups with or without the administration of INCB or silence of STAT3. (JK) The apoptotic rates of different transfected groups with or without silence of STAT3 were measured by flow cytometry. (L) Immunohistochemical staining of KIF20A and p-STAT3 in an independent set of CRC tumor samples with good or poor responses to 5-FU and oxaliplatin therapy. Scale bar=50 μm. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01.